APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs of UDCA and t-UDCA

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Drugs of UDCA and t-UDCA Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17398663032 January 2026193 pages

Choose your research edition.

Industry ResearchDrugs of UDCA and t-UDCA Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs of UDCA and t-UDCA Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Drugs of UDCA and t-UDCA Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs of UDCA and t-UDCA Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs of UDCA and t-UDCA Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Drugs of UDCA and t-UDCA market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Drugs of UDCA and t-UDCA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs of UDCA and t-UDCA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs of UDCA and t-UDCA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Drugs of UDCA and t-UDCA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs of UDCA and t-UDCA include Bruschettini, Daewoong Pharmaceutical, Dr. Falk Pharma, Epic Pharma, Grindeks, Impax, Lannett, Mitsubishi Tanabe Pharma and Viatris, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs of UDCA and t-UDCA market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs of UDCA and t-UDCA and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs of UDCA and t-UDCA sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs of UDCA and t-UDCA market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs of UDCA and t-UDCA Segment by Company

Bruschettini

Daewoong Pharmaceutical

Dr. Falk Pharma

Epic Pharma

Grindeks

Impax

Lannett

Mitsubishi Tanabe Pharma

Viatris

Shanghai Pharma

Teva

Drugs of UDCA and t-UDCA Segment by Type

t-UDCA

UDCA

Drugs of UDCA and t-UDCA Segment by Application

Hepatopathy

Gallstone

Biliary Disease

Other

Drugs of UDCA and t-UDCA Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs of UDCA and t-UDCA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs of UDCA and t-UDCA and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs of UDCA and t-UDCA.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs of UDCA and t-UDCA market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs of UDCA and t-UDCA manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Drugs of UDCA and t-UDCA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Drugs of UDCA and t-UDCA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Drugs of UDCA and t-UDCA Industry Trends Table 2. Drugs of UDCA and t-UDCA Industry Drivers Table 3. Drugs of UDCA and t-UDCA Industry Opportunities and Challenges Table 4. Drugs of UDCA and t-UDCA Industry Restraints Table 5. Global Drugs of UDCA and t-UDCA Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Drugs of UDCA and t-UDCA Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Drugs of UDCA and t-UDCA Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Drugs of UDCA and t-UDCA Sales Market Share by Manufacturers Table 9. Global Drugs of UDCA and t-UDCA Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Drugs of UDCA and t-UDCA Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Drugs of UDCA and t-UDCA Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Drugs of UDCA and t-UDCA Manufacturers, Product Type & Application Table 13. Global Drugs of UDCA and t-UDCA Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs of UDCA and t-UDCA by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of t-UDCA Table 17. Major Manufacturers of UDCA Table 18. Global Drugs of UDCA and t-UDCA Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Drugs of UDCA and t-UDCA Sales by Type (2021-2026) & (K Units) Table 20. Global Drugs of UDCA and t-UDCA Sales by Type (2027-2032) & (K Units) Table 21. Global Drugs of UDCA and t-UDCA Sales Market Share by Type (2021-2026) Table 22. Global Drugs of UDCA and t-UDCA Sales Market Share by Type (2027-2032) Table 23. Global Drugs of UDCA and t-UDCA Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Drugs of UDCA and t-UDCA Revenue by Type (2021-2026) & (K Units) Table 25. Global Drugs of UDCA and t-UDCA Revenue by Type (2027-2032) & (K Units) Table 26. Global Drugs of UDCA and t-UDCA Revenue Market Share by Type (2021-2026) Table 27. Global Drugs of UDCA and t-UDCA Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hepatopathy Table 29. Major Manufacturers of Gallstone Table 30. Major Manufacturers of Biliary Disease Table 31. Major Manufacturers of Other Table 32. Global Drugs of UDCA and t-UDCA Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Drugs of UDCA and t-UDCA Sales by Application (2021-2026) & (K Units) Table 34. Global Drugs of UDCA and t-UDCA Sales by Application (2027-2032) & (K Units) Table 35. Global Drugs of UDCA and t-UDCA Sales Market Share by Application (2021-2026) Table 36. Global Drugs of UDCA and t-UDCA Sales Market Share by Application (2027-2032) Table 37. Global Drugs of UDCA and t-UDCA Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Drugs of UDCA and t-UDCA Revenue by Application (2021-2026) & (K Units) Table 39. Global Drugs of UDCA and t-UDCA Revenue by Application (2027-2032) & (K Units) Table 40. Global Drugs of UDCA and t-UDCA Revenue Market Share by Application (2021-2026) Table 41. Global Drugs of UDCA and t-UDCA Revenue Market Share by Application (2027-2032) Table 42. Global Drugs of UDCA and t-UDCA Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Drugs of UDCA and t-UDCA Sales by Region (2021-2026) & (K Units) Table 44. Global Drugs of UDCA and t-UDCA Sales Market Share by Region (2021-2026) Table 45. Global Drugs of UDCA and t-UDCA Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Drugs of UDCA and t-UDCA Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Drugs of UDCA and t-UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Drugs of UDCA and t-UDCA Sales by Country (2021-2026) & (K Units) Table 49. North America Drugs of UDCA and t-UDCA Sales by Country (2027-2032) & (K Units) Table 50. Europe Drugs of UDCA and t-UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Drugs of UDCA and t-UDCA Sales by Country (2021-2026) & (K Units) Table 52. Europe Drugs of UDCA and t-UDCA Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Drugs of UDCA and t-UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Drugs of UDCA and t-UDCA Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Drugs of UDCA and t-UDCA Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Drugs of UDCA and t-UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Drugs of UDCA and t-UDCA Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Drugs of UDCA and t-UDCA Sales by Country (2027-2032) & (K Units) Table 59. Global Drugs of UDCA and t-UDCA Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Drugs of UDCA and t-UDCA Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Drugs of UDCA and t-UDCA Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Drugs of UDCA and t-UDCA Revenue Market Share by Region (2021-2026) Table 63. Global Drugs of UDCA and t-UDCA Revenue Market Share by Region (2027-2032) Table 64. Bruschettini Company Information Table 65. Bruschettini Business Overview Table 66. Bruschettini Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bruschettini Drugs of UDCA and t-UDCA Product Portfolio Table 68. Bruschettini Recent Development Table 69. Daewoong Pharmaceutical Company Information Table 70. Daewoong Pharmaceutical Business Overview Table 71. Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Product Portfolio Table 73. Daewoong Pharmaceutical Recent Development Table 74. Dr. Falk Pharma Company Information Table 75. Dr. Falk Pharma Business Overview Table 76. Dr. Falk Pharma Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Dr. Falk Pharma Drugs of UDCA and t-UDCA Product Portfolio Table 78. Dr. Falk Pharma Recent Development Table 79. Epic Pharma Company Information Table 80. Epic Pharma Business Overview Table 81. Epic Pharma Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Epic Pharma Drugs of UDCA and t-UDCA Product Portfolio Table 83. Epic Pharma Recent Development Table 84. Grindeks Company Information Table 85. Grindeks Business Overview Table 86. Grindeks Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Grindeks Drugs of UDCA and t-UDCA Product Portfolio Table 88. Grindeks Recent Development Table 89. Impax Company Information Table 90. Impax Business Overview Table 91. Impax Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Impax Drugs of UDCA and t-UDCA Product Portfolio Table 93. Impax Recent Development Table 94. Lannett Company Information Table 95. Lannett Business Overview Table 96. Lannett Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Lannett Drugs of UDCA and t-UDCA Product Portfolio Table 98. Lannett Recent Development Table 99. Mitsubishi Tanabe Pharma Company Information Table 100. Mitsubishi Tanabe Pharma Business Overview Table 101. Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Product Portfolio Table 103. Mitsubishi Tanabe Pharma Recent Development Table 104. Viatris Company Information Table 105. Viatris Business Overview Table 106. Viatris Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Viatris Drugs of UDCA and t-UDCA Product Portfolio Table 108. Viatris Recent Development Table 109. Shanghai Pharma Company Information Table 110. Shanghai Pharma Business Overview Table 111. Shanghai Pharma Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Shanghai Pharma Drugs of UDCA and t-UDCA Product Portfolio Table 113. Shanghai Pharma Recent Development Table 114. Teva Company Information Table 115. Teva Business Overview Table 116. Teva Drugs of UDCA and t-UDCA Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Teva Drugs of UDCA and t-UDCA Product Portfolio Table 118. Teva Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Drugs of UDCA and t-UDCA Distributors List Table 122. Drugs of UDCA and t-UDCA Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Drugs of UDCA and t-UDCA Product Image Figure 2. Global Drugs of UDCA and t-UDCA Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs of UDCA and t-UDCA Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs of UDCA and t-UDCA Sales (2021-2032) & (K Units) Figure 5. Global Drugs of UDCA and t-UDCA Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Drugs of UDCA and t-UDCA Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. t-UDCA Image Figure 9. UDCA Image Figure 10. Global Drugs of UDCA and t-UDCA Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Drugs of UDCA and t-UDCA Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs of UDCA and t-UDCA Sales Market Share by Type (2021-2032) Figure 13. Global Drugs of UDCA and t-UDCA Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Drugs of UDCA and t-UDCA Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Drugs of UDCA and t-UDCA Revenue Market Share by Type (2021-2032) Figure 16. Hepatopathy Image Figure 17. Gallstone Image Figure 18. Biliary Disease Image Figure 19. Other Image Figure 20. Global Drugs of UDCA and t-UDCA Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Drugs of UDCA and t-UDCA Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Drugs of UDCA and t-UDCA Sales Market Share by Application (2021-2032) Figure 23. Global Drugs of UDCA and t-UDCA Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Drugs of UDCA and t-UDCA Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Drugs of UDCA and t-UDCA Revenue Market Share by Application (2021-2032) Figure 26. North America Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Drugs of UDCA and t-UDCA Sales Market Share by Country (2021-2032) Figure 28. U.S. Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Drugs of UDCA and t-UDCA Sales Market Share by Country (2021-2032) Figure 33. Germany Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Drugs of UDCA and t-UDCA Sales Market Share by Country (2021-2032) Figure 40. China Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Drugs of UDCA and t-UDCA Sales Market Share by Country (2021-2032) Figure 48. Brazil Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Drugs of UDCA and t-UDCA Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Drugs of UDCA and t-UDCA Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Drugs of UDCA and t-UDCA Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Drugs of UDCA and t-UDCA Revenue (2021-2032) & (US$ Million) Figure 59. North America Drugs of UDCA and t-UDCA Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Drugs of UDCA and t-UDCA Revenue (2021-2032) & (US$ Million) Figure 61. Europe Drugs of UDCA and t-UDCA Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Drugs of UDCA and t-UDCA Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Drugs of UDCA and t-UDCA Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Drugs of UDCA and t-UDCA Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Drugs of UDCA and t-UDCA Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Drugs of UDCA and t-UDCA Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Drugs of UDCA and t-UDCA Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • t-UDCA
  • UDCA
Applications
  • Hepatopathy
  • Gallstone
  • Biliary Disease
  • Other
Companies covered
  • Bruschettini
  • Daewoong Pharmaceutical
  • Dr. Falk Pharma
  • Epic Pharma
  • Grindeks
  • Impax
  • Lannett
  • Mitsubishi Tanabe Pharma
  • Viatris
  • Shanghai Pharma
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs of UDCA and t-UDCA Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs of UDCA and t-UDCA Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Drugs of UDCA and t-UDCA Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Drugs of UDCA and t-UDCA Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Drugs of UDCA and t-UDCA Market Dynamics
  1. 2.1 Drugs of UDCA and t-UDCA Industry Trends
  2. 2.2 Drugs of UDCA and t-UDCA Industry Drivers
  3. 2.3 Drugs of UDCA and t-UDCA Industry Opportunities and Challenges
  4. 2.4 Drugs of UDCA and t-UDCA Industry Restraints
3 Drugs of UDCA and t-UDCA Market by Manufacturers
  1. 3.1 Global Drugs of UDCA and t-UDCA Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Drugs of UDCA and t-UDCA Sales by Manufacturers (2021-2026)
  3. 3.3 Global Drugs of UDCA and t-UDCA Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Drugs of UDCA and t-UDCA Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs of UDCA and t-UDCA Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Drugs of UDCA and t-UDCA Manufacturers, Product Type & Application
  7. 3.7 Global Drugs of UDCA and t-UDCA Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs of UDCA and t-UDCA Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs of UDCA and t-UDCA Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs of UDCA and t-UDCA Tier 1, Tier 2, and Tier 3
4 Drugs of UDCA and t-UDCA Market by Type
  1. 4.1 Drugs of UDCA and t-UDCA Type Introduction
  2. 4.1.1 t-UDCA
  3. 4.1.2 UDCA
  4. 4.2 Global Drugs of UDCA and t-UDCA Sales by Type
  5. 4.2.1 Global Drugs of UDCA and t-UDCA Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drugs of UDCA and t-UDCA Sales by Type (2021-2032)
  7. 4.2.3 Global Drugs of UDCA and t-UDCA Sales Market Share by Type (2021-2032)
  8. 4.3 Global Drugs of UDCA and t-UDCA Revenue by Type
  9. 4.3.1 Global Drugs of UDCA and t-UDCA Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Drugs of UDCA and t-UDCA Revenue by Type (2021-2032)
  11. 4.3.3 Global Drugs of UDCA and t-UDCA Revenue Market Share by Type (2021-2032)
5 Drugs of UDCA and t-UDCA Market by Application
  1. 5.1 Drugs of UDCA and t-UDCA Application Introduction
  2. 5.1.1 Hepatopathy
  3. 5.1.2 Gallstone
  4. 5.1.3 Biliary Disease
  5. 5.1.4 Other
  6. 5.2 Global Drugs of UDCA and t-UDCA Sales by Application
  7. 5.2.1 Global Drugs of UDCA and t-UDCA Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Drugs of UDCA and t-UDCA Sales by Application (2021-2032)
  9. 5.2.3 Global Drugs of UDCA and t-UDCA Sales Market Share by Application (2021-2032)
  10. 5.3 Global Drugs of UDCA and t-UDCA Revenue by Application
  11. 5.3.1 Global Drugs of UDCA and t-UDCA Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Drugs of UDCA and t-UDCA Revenue by Application (2021-2032)
  13. 5.3.3 Global Drugs of UDCA and t-UDCA Revenue Market Share by Application (2021-2032)
6 Global Drugs of UDCA and t-UDCA Sales by Region
  1. 6.1 Global Drugs of UDCA and t-UDCA Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs of UDCA and t-UDCA Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs of UDCA and t-UDCA Sales by Region (2021-2026)
  4. 6.2.2 Global Drugs of UDCA and t-UDCA Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs of UDCA and t-UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Drugs of UDCA and t-UDCA Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Drugs of UDCA and t-UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Drugs of UDCA and t-UDCA Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Drugs of UDCA and t-UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Drugs of UDCA and t-UDCA Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Drugs of UDCA and t-UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Drugs of UDCA and t-UDCA Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Drugs of UDCA and t-UDCA Revenue by Region
  1. 7.1 Global Drugs of UDCA and t-UDCA Revenue by Region
  2. 7.1.1 Global Drugs of UDCA and t-UDCA Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Drugs of UDCA and t-UDCA Revenue by Region (2021-2026)
  4. 7.1.3 Global Drugs of UDCA and t-UDCA Revenue by Region (2027-2032)
  5. 7.1.4 Global Drugs of UDCA and t-UDCA Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Drugs of UDCA and t-UDCA Revenue (2021-2032)
  8. 7.2.2 North America Drugs of UDCA and t-UDCA Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Drugs of UDCA and t-UDCA Revenue (2021-2032)
  11. 7.3.2 Europe Drugs of UDCA and t-UDCA Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Drugs of UDCA and t-UDCA Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Drugs of UDCA and t-UDCA Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Drugs of UDCA and t-UDCA Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Drugs of UDCA and t-UDCA Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bruschettini
  2. 8.1.1 Bruschettini Company Information
  3. 8.1.2 Bruschettini Business Overview
  4. 8.1.3 Bruschettini Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bruschettini Drugs of UDCA and t-UDCA Product Portfolio
  6. 8.1.5 Bruschettini Recent Developments
  7. 8.2 Daewoong Pharmaceutical
  8. 8.2.1 Daewoong Pharmaceutical Company Information
  9. 8.2.2 Daewoong Pharmaceutical Business Overview
  10. 8.2.3 Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Product Portfolio
  12. 8.2.5 Daewoong Pharmaceutical Recent Developments
  13. 8.3 Dr. Falk Pharma
  14. 8.3.1 Dr. Falk Pharma Company Information
  15. 8.3.2 Dr. Falk Pharma Business Overview
  16. 8.3.3 Dr. Falk Pharma Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Dr. Falk Pharma Drugs of UDCA and t-UDCA Product Portfolio
  18. 8.3.5 Dr. Falk Pharma Recent Developments
  19. 8.4 Epic Pharma
  20. 8.4.1 Epic Pharma Company Information
  21. 8.4.2 Epic Pharma Business Overview
  22. 8.4.3 Epic Pharma Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Epic Pharma Drugs of UDCA and t-UDCA Product Portfolio
  24. 8.4.5 Epic Pharma Recent Developments
  25. 8.5 Grindeks
  26. 8.5.1 Grindeks Company Information
  27. 8.5.2 Grindeks Business Overview
  28. 8.5.3 Grindeks Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Grindeks Drugs of UDCA and t-UDCA Product Portfolio
  30. 8.5.5 Grindeks Recent Developments
  31. 8.6 Impax
  32. 8.6.1 Impax Company Information
  33. 8.6.2 Impax Business Overview
  34. 8.6.3 Impax Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Impax Drugs of UDCA and t-UDCA Product Portfolio
  36. 8.6.5 Impax Recent Developments
  37. 8.7 Lannett
  38. 8.7.1 Lannett Company Information
  39. 8.7.2 Lannett Business Overview
  40. 8.7.3 Lannett Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lannett Drugs of UDCA and t-UDCA Product Portfolio
  42. 8.7.5 Lannett Recent Developments
  43. 8.8 Mitsubishi Tanabe Pharma
  44. 8.8.1 Mitsubishi Tanabe Pharma Company Information
  45. 8.8.2 Mitsubishi Tanabe Pharma Business Overview
  46. 8.8.3 Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Product Portfolio
  48. 8.8.5 Mitsubishi Tanabe Pharma Recent Developments
  49. 8.9 Viatris
  50. 8.9.1 Viatris Company Information
  51. 8.9.2 Viatris Business Overview
  52. 8.9.3 Viatris Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Viatris Drugs of UDCA and t-UDCA Product Portfolio
  54. 8.9.5 Viatris Recent Developments
  55. 8.10 Shanghai Pharma
  56. 8.10.1 Shanghai Pharma Company Information
  57. 8.10.2 Shanghai Pharma Business Overview
  58. 8.10.3 Shanghai Pharma Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai Pharma Drugs of UDCA and t-UDCA Product Portfolio
  60. 8.10.5 Shanghai Pharma Recent Developments
  61. 8.11 Teva
  62. 8.11.1 Teva Company Information
  63. 8.11.2 Teva Business Overview
  64. 8.11.3 Teva Drugs of UDCA and t-UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Teva Drugs of UDCA and t-UDCA Product Portfolio
  66. 8.11.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs of UDCA and t-UDCA Value Chain Analysis
  2. 9.1.1 Drugs of UDCA and t-UDCA Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs of UDCA and t-UDCA Production Mode & Process
  6. 9.2 Drugs of UDCA and t-UDCA Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs of UDCA and t-UDCA Distributors
  9. 9.2.3 Drugs of UDCA and t-UDCA Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst